Clinical Trial Finder

Inclusion Criteria:

1. Has medical insurance that covers this standard of care procedure and all other anticipated and unanticipated procedure-related care, and all coverage criteria required by insurer are met, which may include but are not limited to:

• - Has had low back and/or buttock pain for at least 6 months that is inadequately responsive to non-surgical care.

• - Has a positive Fortin's test.

• - Has a diagnosis of SIJ dysfunction (degenerative sacroiliitis or SI disruption) with pain elicited on at least 3 of 5 provocative tests (FABER, Gaenslen, Distraction, Thigh Thrust, Compression).

• - At least 75% reduction in pain for the expected duration of two anesthetics (on separate visits each with a different duration of action), and the ability to perform previously painful maneuvers, following an image-guided, contrast-enhanced intra-articular (diagnostic) SIJ injection.

• - A trial of at least one therapeutic intra-articular SIJ injection (i.e. corticosteroid injection) 2.

Has an ODI score ≥30% at enrollment. 3. Has a SI joint pain score of at least 5 out of 10 on numerical rating scale at enrollment. 4. Be at least 21 years of age at enrollment. 5. The patient's physician has decided that the best treatment for the patient's SIJ dysfunction is the Nevro1 SI Fixation System, and the patient has agreed to the treatment. 6. Be willing and capable of giving written informed consent. 7. Be mentally and physically able to comply with study-related requirements and procedures and attend all scheduled visits.

Exclusion Criteria:

1. Has current severe back pain due to other causes, such as lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, lumbar radicular pain, and lumbar vertebral body fracture. 2. Has SIJ pain secondary to inflammatory conditions or other known sacroiliac pathology such as: Sacral dysplasia, inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA-associated spondylo-arthropathy), tumor, infection, acute fracture, and crystal arthropathy. 3. Has had a previous SIJ implant placement, including an allograft. 4. Has had an injection with corticosteroid into the index SIJ within the last 30 days. 5. Has had a sacral radiofrequency ablation within the last 6 months. 6. Has a history of recent (<1 year) major trauma to pelvis. 7. Has previously diagnosed or suspected severe osteoporosis (defined as prior T-score < -2.5 or history of osteoporotic fracture) 8. Has a chronic rheumatologic condition (e.g., rheumatoid arthritis) 9. Has a known allergy to titanium or titanium alloys. 10. Has a current local or systemic infection that raises the risk of surgery. 11. Is currently receiving or seeking short- or long-term worker's compensation related to the SI joint or low back pain, is currently receiving disability remuneration related to SI joint or low back pain, and/or is currently involved in injury litigation related to the SI joint or low back pain. 12. Is participating in an investigational study or has been involved in an investigational study within 3 months prior to enrollment. 13. Has any condition or anatomy that makes treatment with the Nevro1 SI Fixation System infeasible. 14. Is taking a medication known to have detrimental effects on bone quality and soft tissue healing. 15. Has a prominent neurologic condition that would interfere with physical therapy. 16. Be pregnant or plan on becoming pregnant in the next two years. 17. Has a medical condition or pain in other area(s), not intended to be treated in this study, that could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints, as determined by the Investigator

Arms

: Treated Group

Treated with Nevro1 transfixing and fusion system

Interventions

Device: - Sacroiliac Joint transfixing and fusion system (Nevro1)

The Nevro1 is a titanium cage the is implanted in the sacroiliac join from a posterior direction, and then anchors are deployed that stabilize the joint. It has multiple openings to allow surgeons to fill them with autogenous bone graft to encourage bone bridging through the implant for SIJ fusion.